子宮頸癌手術前腔內近接治療為目前該病症臨床大量應用之治療方式,因而本次研究透過熱發光劑量計(thermoluminescent dosimeter,TLD) 對銥-192實際照射測量劑量,並以西弗積分(Sievert integral)線射源計算劑量,對自製術前子宮頸癌近接治療假體水中A 點(Manchester system)進行劑量計測,並進一步與Oncentra Brachy software(OB software)近接治療電腦治療計畫之各參數做比對。比對後發現在TLD實測結果中,A 點實測劑量與OB software 總差異百分比達16.05%,而西弗積分之總差異百分比則達9.92%。雖本次研究以自製假體而有人為誤差的侷限,以及考慮西弗積分雖具有濾器及距離參數修正,卻仍及不上OB software運用的TG-43報告完善之狀況,然而本次研究之結果數據仍以提供往後對子宮頸癌手術前腔內近接治療之相關研究一參考之依據。
Pre-operative brachytherapy is the clinical treatment that has been wildly used in cervical cancer. The study mean to compare the treatment dose at point A of TLD (thermoluminescent dosimeter), Sievert integral and Oncentra Brachy software(OB software) which is the treatment planning system constructed by Elekta company. The study result express the total deviation about 16.05% between TLD detection at point and OB software, 9.92% between Sievert integral and OB software. However cause by the potential error in self-made phantom and the parameter differences between Sievert integral and TG-43 that is the calculation basis of OB software , the study shows its limitation. The researcher expect to provide the data for other feature works.